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Abstract: 
No universal strategy exists for humanizing mouse antibodies, and most approaches are based on primary sequence alignment and 
grafting.  Although  this  strategy  theoretically  decreases  the  immunogenicity  of  mouse  antibodies,  it  neither  addresses 
conformational changes nor steric clashes that arise due to grafting of human germline frameworks to accommodate mouse CDR 
regions. To address these issues, we created and tested a structure-based biologic design approach using a de novo homology 
model to aid in the humanization of 17 unique mouse antibodies. Our approach included building a structure-based de novo 
homology model from the primary mouse antibody sequence, mutation of the mouse framework residues to the closest human 
germline  sequence  and  energy  minimization  by  simulated  annealing  on  the  humanized  homology  model.  Certain  residues 
displayed force field errors and revealed steric clashes upon closer examination. Therefore, further mutations were introduced to 
rationally correct these errors. In conclusion, use of de novo antibody homology modeling together with simulated annealing 
improved the ability to predict conformational and steric clashes that may arise due to conversion of a mouse antibody into the 
humanized form and would prevent its neutralization when administered in vivo. This design provides a robust path towards the 
development of a universal strategy for humanization of mouse antibodies using computationally derived antibody homologous 
structures. 
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Background: 
Antibodies  render  higher  specificity  than  small  molecules 
(drugs) against a given biological target. The mouse is the most 
favored model system for producing specific antibodies to an 
antigen  of  interest.  Mouse  monoclonal  antibodies  (mAb)  are 
routinely  used  not  only  for  diagnostic  purposes  but  also  as 
therapeutic agents. However, administration of mouse mAbs in 
patients  can  lead  to  allergic  reactions  against  the  therapeutic 
antibody, otherwise known as the human anti-mouse antibody 
(HAMA)  response  [1].  To  address  this  problem,  chimeric 
antibodies have been designed, which could lessen the HAMA 
response  but  not  eliminate  it  [2].  Further  engineering  was 
undertaken to replace the mouse scaffold with that of human 
origin  by  transplanting  mouse  complementarity  determining 
regions (CDRs) onto a fully human scaffold  [3]. As the CDR 
paratope  usually  binds  and  engages  the  antigen  epitope,  the 
mouse  CDRs  in  the  humanized  antibody  are  minimally 
exposed to the human immune system and, in theory, should 
be non-allergenic in nature.  
 
Humanization of mouse antibodies refers to the replacement of 
mouse  framework  regions  with  similar  human  germline 
framework  regions  based  on  amino  acid  sequence  similarity. 
The mouse scaffold is replaced with a human scaffold primarily BIOINFORMATION  open access 
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to reduce immunogenicity of the mouse antibody and prevent 
its neutralization when administered to humans. This process 
renders  the  humanized  antibody  with  a  greater  therapeutic 
index  than  its  mouse  counterpart.  Humanization  of  mouse 
antibodies  has  been  shown  to  prolong  the  serum  half-life, 
improve  interactions  with  effector  cells  and  reduce 
immunogenicity.  The  rat  antibody  CAMPATH-1G,  upon 
humanization  (CAMPATH-1H),  demonstrated  not  only  a 
longer half-life but also improved therapeutic effects [4].  
 
Other  strategies  that  have  been  used  to  minimize 
immunogenicity of the humanized antibody include veneering 
and  super-humanization.  In  veneering  (re-surfacing),  the 
mouse  mAb  sequence  in  the  crystal  structure  or  homology 
model is examined for surface exposure or solvent accessibility, 
and the protruding residues (e.g., lysine) are mutated to human 
germline  residues  [5].  This  process  drastically  reduces  the 
immunogenic potential of the humanized antibody. In addition, 
certain mouse CDR residues have been further eliminated via 
the  super-humanization  technique,  which  improved  the 
therapeutic value of the antibodies [6-8].  
 
Current  approaches  for  antibody  humanization  involves 
replacement  of  numerous  mouse  residues  in  the  scaffold,  as 
well as CDR regions, with human antibody-derived residues, 
but the consequences is usually a reduction or in some cases 
complete loss of affinity towards the antigen. Therefore, these 
methods  are  not  viable  options  for  the  conversion  of  mouse 
antibodies to the humanized form, and further optimizations 
are  needed  to  improve  binding  kinetics  of  humanized 
antibodies to match their original parental mouse monoclonal 
antibodies.  Indeed,  antibody  humanization  is  an  iterative 
process that requires engineering at all stages of development 
to produce a successful therapeutic agent.  
 
As an alternative to antibody humanization based on the linear 
sequence,  an  approach  relying  on  the  3D  structure  and 
conformation provides an ideal platform to address the above 
concerns  in  a  rational  manner.  X-ray  crystallography  and 
nuclear magnetic resonance (NMR) imaging are currently the 
only tools that can deduce the 3D structure of antibodies at an 
atomic  level.  However,  these  techniques  require  elaborate 
infrastructure  and  time.  The  rapid  pace  of  deposition  of 
antibody structures in the Protein Data Bank (PDB) has helped 
in the creation of various structure based molecular prediction 
programs for biologics. 
 
De  novo  antibody  structure  prediction  via  homology  model 
building  is  being  used  currently  for  antibody  design, 
engineering and humanization to reduce immunogenicity and 
restore affinities similar to those of parental mouse antibodies.  
This process entails PDB searches, simultaneously carried out 
for both frameworks (scaffold) as well as CDRs for light and 
heavy chains, for the most homologous 3D antibody structure 
to the query sequence and results in the creation of a structure-
based  homology  model  from  the  primary  sequence  of  the 
mouse antibody. These approaches tend to save time from the 
computational  prediction  to  experimental  validation  stages. 
State-of-the art antibody structure prediction programs include 
Web  Antibody  Modeling  (WAM)  [9],  Prediction  of 
Immunoglobulin  Structures  (PIGS)  [10],  Rosetta  Antibody 
Modeling  (RAM)  [11]  and  more  recently  commercially 
developed  algorithms,  such  as  Accelrys  (Discovery  Studio), 
Molecular  Operating  Environment  (MOE),  Schrodinger 
(BioLuminate) and Macromoltek. Although publicly available 
servers help to build a good antibody homology model, they do 
not  contain  any  algorithms  to  further  complete  the 
humanization of mouse antibodies.  
  
To validate the applicability of structure-based biologic design 
as a universal strategy for humanization of mouse antibodies, 
we  applied  our  humanization  strategy  to  17  unique  mouse 
antibodies. In addition, this study highlights the importance of 
conformational  folding  for  antibody  design  given  the 
limitations  of  the  linear  sequence  method.  A  threshold  filter 
was placed to consider only mouse antibody structures released 
in  the  PDB  since  2010  in  order  to  prevent  redundancy  with 
previously  published  studies.  Importantly,  no  benchmark 
studies on antibody structure predictions and homology model 
building as a platform for antibody design for the purpose of 
humanization  of  mouse  antibodies  have  been  reported  since 
that period.  
 
This study involved creation of an antibody homology model 
from  mouse  antibody  primary  sequences  and  subsequently 
introduced mutations to match the most highly similar human 
germline  gene  sequence.  Furthermore,  a  surface  accessibility 
screen  was  performed  to  locate  conformationally  exposed 
residues,  and  they  were  mutated  to  minimize  or  eliminate 
potential  immunogenicity.  This  humanized  model  was  then 
subjected  to  simulated  annealing  (energy  minimization).  In 
order  to  synchronize  the  structural  disparity  between  the 
human  scaffold  with  mouse  CDRs,  simulated  annealing  was 
performed to energetically minimize this hybrid structure. This 
procedure allowed the homology model to fold systematically 
and mimic the most favorable native conformation state. Force 
field errors resulting from this simulation were then observed 
for  further  analysis  and  optimization.  Therefore,  this  study 
extends  our  knowledge  of  antibody  design  for  purposes  of 
converting  mouse  antibodies  to  fully  accommodate  a  human 
germline  scaffold  for  therapeutic  drug  development.  It  also 
demonstrates  the  advantages  of  coupling  structure-based 
antibody  design  with  simulated  annealing  (energy 
minimizations) for the deduction of important conformational 
residues  required  for  proper  antibody  folding,  function  and 
affinity. 
 
Methodology: 
Mouse antibody sequences and structures  
Mouse  Fab  (fragment  antigen  binding)  antibody  structures 
were  searched  in  the  Protein  Data  Bank  (PDB).    In  order  to 
prevent  any  redundancy  in  antibody  modeling  with  earlier 
studies, only mouse antibodies released since 2010 were taken 
for  further  evaluation.  Out  of  104  mouse  antibody-antigen 
crystal structures, 17 unique unbound mouse antibodies were 
chosen randomly for the final study.  
 
Prediction of Immunoglobulin Structures (PIGS)  
Each  mouse  antibody  sequence  obtained  from  the  PDB  as  a 
FASTA file was truncated to contain only the variable heavy 
and light chain sequences (Fv, fragment variable format) and 
submitted to the PIGS server (http: // www.biocomputing.it/ 
pigs/) via single sequence submission. Default server settings 
were used for template selection and generation. Top scoring BIOINFORMATION  open access 
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heavy and light chain templates were chosen from 20 templates 
displayed. These mouse homology models were then subjected 
to a surface accessibility screen set at a threshold of 30% using 
Swiss-PdbViewer to determine the location of various surface 
accessible residues, which may be immunogenic in nature [12]. 
 
Rosetta antibody modeling (RAM) 
Mouse FASTA sequences for the heavy chain and light chain 
were submitted in the Fv format to the Rosetta Online Server 
that  Includes  Everyone  (ROSIE)  antibody  modeling  server 
(http://antibody.graylab.jhu.edu)  [13].  The  first  antibody 
model was selected among the top ten scoring antibody models 
based on their energy minimization scores. Root mean square 
deviation  (RMSD)  scores  were  calculated  using  the  PyMOL 
built-in combinatorial extension (CE) module alignment tool to 
gauge the validity and model prediction properties as shown in 
Supplementary  Table  1  (see  supplementary  material).  In 
addition,  PDBsum  structural  analysis  with  PROCHECK  and 
Verify3D  programs  were  used  to  validate  the  homology 
models. All homology models are available upon request. 
 
Humanization 
The IMGT DomainGap alignment module was used to find and 
align  each  mouse  sequence  to  the  most  homologous  human 
germline  sequence  (http://www.imgt.org/3Dstructure-DB/ 
cgi/DomainGapAlign.cgi)  [14].  Except  the  CDR  regions, 
mutations were manually introduced in the mouse framework 
regions of the homology model to match the human germline 
sequence  via  the  PyMOL  mutagenesis  wizard  tool. 
Furthermore, a surface accessibility screen was performed, and 
the identified surface-exposed mouse residues were manually 
mutated to reflect the human germline sequence.  
 
Numbering of antibodies   
The  IMGT  database  unique  Lefranc  numbering  system  for 
antibodies was used for sequence alignment. Antibody crystal 
structures derived from the PDB have Kabat numbering, and 
homology  models  generated  via  the  PIGS  server  have  the 
Kabat-Chothia numbering scheme. Meanwhile, the RAM server 
utilizes the Chothia numbering scheme. 
 
Energy minimization 
The  Swiss-PdbViewer  (DeepView)  software was  downloaded 
and run locally for energy minimization (simulated annealing) 
[12].  The  humanized  homology  model  was  subjected  to  the 
GROMOS  force  field  energy  minimization.  Default  settings 
were  used,  and  the  output  model  was  further  examined  for 
residues with various force field errors, which were displayed 
by energy minimized model. These residues were individually 
examined  via  PyMOL.  Mutations  were  then  introduced  to 
rationally  correct  select  steric  clashes,  which  were  predicted 
after  simulated  annealing.  All  homology  models  were  again 
subjected  to  force  field  simulated  annealing  to  validate  the 
chosen mutations or substitutions. 
 
Results: 
A total of 17 mouse antibody homology models generated via 
the  PIGS  and  RAM  servers  were  carefully  examined  for 
modeling errors. Among these, the 3I75 model obtained via the 
PIGS server, as well as the 4DCQ and 3MNV models via the 
RAM  server,  contained  a  broken  chain  or  modeling  failure. 
Therefore, they were omitted from the rest of the study (Table 
1).  The  amino  acid  sequence  alignment  of  the  17  different 
mouse  antibody  sequences  with  the  closest  human  germline 
sequence found in the IMGT database revealed a high sequence 
similarity in the heavy and light chains with ~60% identity or 
higher to the human germline sequence (Figure 1a). This high 
level  of  sequence  identity  was  crucial  in  minimizing  the 
mutations required for humanization of the mouse antibodies. 
The  human  germline  sequence  with  the  highest  Smith-
Waterman  score  obtained  via  IMGT/DomainGap  alignment 
through the IMGT database was selected as a final template for 
humanization  of  the  mouse  antibody  Table  2  (see 
supplementary material).  
 
 
Figure  1:    Sequence  and  structural  alignment  of  mouse 
antibody 3UJT. A) 3UJT heavy and light chains were sequence 
aligned  to  the  most  homologous  human  germline  genes 
IGHV1-2*02  and  IGKV4-1*01,  respectively,  via  IMGT 
DomainGap alignment. 28 mutations (shaded red) in the heavy 
chain and 16 in the light chain were made to humanize (green) 
the mouse antibody 3UJT. CDRs (yellow) were unchanged; B) 
Structural  alignment  of  the  mouse  antibody  3UJT  crystal 
structure (gray) and mouse homology models generated via the 
PIGS (purple) and RAM (blue) servers. RMSD between the Cα 
backbones of the crystal structure (grey) and PIGS homology 
model (purple) was 0.9 Å, whereas that for the RAM homology 
model (blue) was 2.5 Å over 224 residues. 
 
Furthermore,  RMSD  analysis  between  the  X-ray  crystal 
structure (PDB) and mouse homology models generated from 
the  PIGS  and  RAM  servers  via  PyMOL  revealed  a  deviation 
between  the  Cα  backbones  (3.3  Å  maximum  and  of  0.7  Å 
minimum deviation over > 200 residues) as shown in Figure 1b 
and  (Table  1).  Therefore,  these  antibody  homology  models 
appeared  to  be  relatively  reliable  for  generating  the  overall 
tertiary  fold  and  homologous  structures.  In  addition,  certain 
solvent accessible residues (outside the CDR regions) revealed 
from  a  surface  accessibility  screen  of  the  mouse  homology 
model  were  manually  mutated  to  the  human  germline 
sequence to reduce or avoid immunogenicity (Figure 2).  BIOINFORMATION  open access 
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The humanized homology model exhibited various force field 
problems  when  subjected  to  simulate  annealing.  Further 
examination of these problems in the energy minimized model 
revealed  steric  clashes,  unfavorable  geometry  and  incorrect 
hydrogen  bonding  (Figure  3a).  These  residues  were  either 
mutated  to  the  parental  mouse  sequence  (back  mutation)  or 
substituted with similar amino acids. The “back mutations” or 
substitutions  did  ameliorate  these  force  field  errors  in  the 
humanized  antibodies.  As  shown  in  (Figure  3b),  the 
humanized  homology  model  3UJT  generated  via  the  PIGS 
server indicated a close proximity between residues Val13 and 
Leu78  in  the  light  chain  of  3UJT.  Therefore,  Val13  was  back 
mutated to Met13, its parental mouse residue, which corrected 
the proximity error. In addition, Asn57 was substituted to Gln50 
to resolve the steric clash between the Trp50 and Asn57 residues 
in the heavy chain (Figure 3c).  
 
Output data of the GROMOS force field simulated annealing 
(energy  minimization)  revealed  that  most  of  the  force  field 
errors  originated  from  the  “non-bonded”  parameter. 
Humanization performed through antibody homology models 
generated  by  the  PIGS  server  had  significantly  more  steric 
clashes compared to that from the RAM server (Supplementary 
Figure  1).  When  these  residues  were  closely  examined,  a 
suitable mutation or substitution seemed to dramatically lower 
the  non-bonded  energies,  hence  energetically  stabilizing  the 
antibody molecule. 
 
 
Figure 2: Strategy for humanization of a mouse antibody based 
on  in  silico  homology  modeling  and  energy  minimizations 
(simulated annealing). The mouse Fv sequence was submitted 
to the PIGS/RAM server to generate a homology model, and 
IMGT DomainGap alignment module was used for sequence 
alignment  to  identify  the  most  homologous  human  germline 
sequence. Mutations were made in the framework regions (red) 
to humanize the mouse antibody model. The Swiss-PdbViewer 
(DeepView)  energy  minimization  tool  was  applied  to  the 
humanized  homology  model  to  find  force  field  errors  in  the 
model.  The  identified  residues  were  carefully  examined  and 
rationally mutated (green) to correct the force field errors in the 
humanized homology model. 
 
 
Figure  3:  GROMOS  force  field  errors  and  rationally  chosen 
mutations  to  correct  them.  A)  Simulated  annealing  of  a 
humanized antibody (PdbID-3UJT) revealed force field errors 
highlighted  in  red/yellow/orange.  These  errors  range  from 
steric clashes, unfavorable geometry and irrelevant hydrogen 
bonding; B) Upon humanization of the light chain framework1, 
residue Val13 was in close proximity with Leu78 of framework3 
in  the  light  chain.  Therefore,  Val13     was  back  mutated  to  its 
parental mouse residue Met13, corrects the clash; C) Humanized 
residue Asn57 in framework3 of the heavy chain clashed with 
Trp50 in framework2 of the heavy chain. Therefore, Asn57 was 
back mutated (mouse) to Gln57.  
 
Discussion: 
The majority of approaches for conversion of a mouse antibody 
to humanized form are based either on sequence or structure 
guided  methods.  These  strategies  help  reduce  the 
immunogenicity of mouse antibodies but fail to address the loss 
of  affinity  usually  observed  using  this  procedure.  To  our 
knowledge,  antibody  humanization  servers  are  not  publicly 
available.  Accordingly,  our  study  lays  the  platform  for 
generalized  structure  guided  homology  model  based 
predictions,  coupled  with  simulated  annealing  for 
humanization  of  mouse  antibodies,  which  can  be  easily 
adapted.  For  the  current  study,  the  RAM  and  PIGS  servers 
were  used  for  the  prediction  and  generation  of  antibody 
homology models. For each antibody, the first model among 
the top 10 models generated via the RAM and PIGS servers was 
selected for this study. 
  
Most humanization strategies tend to rely heavily on primary 
sequence differences, rather than conformational folding. The 
former  sequence-based  strategy  may  lead  to  minimized 
immunogenicity,  but  the  humanized  antibody  may  be 
improperly folded, resulting in loss or reduced affinity towards 
the  target.  Antibody  humanization  undertaken  by  homology 
model  building  alone  does  offer  information  on  the  overall 
folding,  conformation  and  delineation  of  surface  exposed 
residues.  However,  humanization  of  antibodies  via  sequence 
alignment  and  homology  model  generation  with 
conformational  sampling,  together  with  the  simulated 
annealing  approach,  offer  additional  knowledge-based BIOINFORMATION  open access 
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information.  This  approach  provides  a  rational  strategy  to 
correct mutations that not only aid in antibody folding but also 
improve overall kinetics for antigen binding.  
 
Critical  Assessment  of  Protein  Structure  Prediction  (CASP) 
studies and other investigators have shown independently that 
all  of  the  publicly  available  antibody  homology  servers  (i.e., 
WAM,  RAM  and  PIGS)  generate  very  similar  homology 
models,  and  none  of  them  can  accurately  predict  the  loop 
conformation of the CDR3 of the heavy chain (CDRH3) [15-16]. 
Simulated  annealing  is  a  powerful  tool  to  be  used  after 
homology modeling for humanization of a mouse antibody to 
examine  the  effects  of  individual  mutations.  Most 
humanization  methods  omit  this  important  step  that  can 
potentially  hinder  their  antibody  kinetics  against  a  cognate 
target. In this study, homology models generated via the RAM 
server  had  fewer  steric  clashes  compared  to  those  from  the 
PIGS server upon humanization of the mouse antibodies. This 
finding may be attributed to additional optimization protocols 
utilized  in  the  RAM  server,  which  include  simultaneous 
optimizations of the VH/VL orientation, side chain and loop 
backbone. The PIGS server usually generates rigid homology 
models, which frequently contain steric clashes. 
 
As  with  most  computational  predictive  studies,  certain 
limitations exist in this study as well. In silico predictions can 
reveal potential problems in humanization of mouse antibodies 
as  a  proof  of  concept,  but  those  predictions  need  to  be 
experimentally  validated.  Homology  model-based 
humanization of antibodies has been successfully demonstrated 
computationally,  as  well  as  validated  experimentally  in  the 
recent  past  [7-8,  17].  Mader  et  al.  utilized  CDR  grafting  to 
humanize  mouse antibodies along  with  the above-mentioned 
methods and demonstrated that conservative CDR grafting via 
a homology model-based design could restore affinities similar 
to  the  parental  mouse/chimeric  version,  whereas  aggressive 
super-humanization led to complete loss or reduced affinity.  
 
Conclusion: 
The intricate process of humanizing mouse antibodies requires 
rational  introduction  of  amino  acid  substitutions  to  not  only 
correct  force  field  errors  but  also  to  minimize  immunogenic 
reactions  or  anti-drug  responses  against  the  humanized 
antibody.  This  study  highlights  the  importance  of  certain 
canonical and non-canonical residues responsible for the loss of 
affinity and addresses antibody protein folding problems. Our 
results  also  confirmed  previous  studies  that  revealed  the 
benefit of simulated annealing after humanization of a mouse 
homology model [7, 8]. This step pinpoints the importance of 
certain force fields, as well as contributions of certain residues 
in  the  overall  folding  and  kinetics  of  antibody-antigen 
interactions.  For  example,  framework  residues  that  are 
determined  to  interact  and  contribute  to  the  overall 
conformation of the CDR loops may be reverted back to mouse 
residues during the process of humanization [17-20]. Predictive 
structure guided homology models such as those developed in 
this work help to save time and effort through rapid in silico 
predictions  and  screening  which  act  as  a  rational  guide  for 
specific  experimental  validations.  Thus,  structure-based 
predictive  antibody  homology  modeling  and  force  field 
simulated annealing strategies may be adopted universally for 
antibody humanization due to their ease of use and efficiency. 
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Supplementary material: 
 
Supplementary Figure 1:  Steric clashes in antibody homology models generated via PIGS and RAM servers upon humanization. 
Each of the 17 humanized antibodies when subjected to energy minimization (simulated annealing) revealed various steric clashes. 
Generally, humanization performed via the RAM server resulted in fewer steric clashes than PIGS server.  
 
 
Table 1: Seventeen unique mouse antibodies selected for humanization. 
4DCQ, 3MNV and 3I75 mouse sequences failed to generate intact homology models in the RAMS and PIGS servers respectively. 
R.M.S.D analysis was performed between all Cα crystal structures and homology models generated via the PIGS and RAM server. 
On average 23 residues in the heavy chain and 21 residues in the light chain of the mouse antibody were mutated for humanization 
PDB ID  Antigen specific antibody  Resolution Å  Residue Size  R.M.S.D PDB vsPIGS  R.M.S.D  PDBvsRAM 
3UJT  O-antigen  of  Francisella 
tularensis 
2.1  224  0.9  2.5 
4EBQ  Vaccinia virus  1.6  224  1  2.4 
3S62  Plasmodium  vivax  P25 
protein 
4.1  216  1.3  2.6 
4DCQ  Extended  polyglutamine 
(PolyQ) repeats 
1.9  208  2.8  Failed 
3SGD  Trypanosoma  cruzi  P2  beta 
protein 
2.3  200  3  3.2 
2XKN  Epidermal  growth  factor 
receptor (EGFR) 
1.4  216  3.2  3 
3NZ8  HIV-2-associated  protein 
gp125 
2.7  232  1.4  1.2 
3L7E  IL-13  2.5  208  3  3 
3MNV  HIV-1  gp41  membrane-
proximal external region 
2.4  208  3.3  Failed 
3OZ9  HIV- gp41  1.6  216  1.6  1.1 
3O11  Amyloid beta peptide  2.8  200  2.9  2.9 
3OJD  Indolicidin-  (antimicrobial 
peptide) 
2  208  3  2.9 
3NTC  HIV envelope (ENV) - gp120 
- V3 loop 
1.5  224  1.3  2.3 
3I75  Unknown  1.9  208  Failed  3.1 
3MBX  Chimeric dual antigens- IL-13 
and EMMPRIN 
1.6  232  1  2.4 
3MXV  Sonic hedgehog (shh)  1.9  224  1.9  1.3 
3GNM  Thompson-Friedenreich 
antigen 
2.1  224  0.7  1 
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Table  2:  Mouse  monoclonal  antibody  alleles  and  their  target  human  scaffolds  selected  for  humanization  using  the 
IMGT/DomainGap alignment module. Each mouse antibody sequence (amino acid) was queried to obtain its allele as well as the 
most similar (identical) human germline scaffold sequence using the IMGT database. 
 